12:00 AM
Sep 24, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Delafloxacin regulatory update

FDA granted the first publically announced Qualified Infectious Disease Product (QIDP) designation to delafloxacin from Rib-X to treat acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia...

Read the full 129 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >